Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Public ClinicalTrials.gov record NCT02219711. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles. During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed; during the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, non small cell lung cancer and head and neck cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene. In addition patients with clear cell renal cell carcinoma refractory to angiogenesis inhibitors or metastatic prostate cancer with bone metastasis will be enrolled.
Study identification
- NCT ID
- NCT02219711
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 193 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2014 (Type not available)
- Primary completion
- Apr 27, 2022 (Actual)
- Completion
- Apr 27, 2022 (Actual)
- Last update posted
- Mar 6, 2023
2014 – 2022
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| University of California, San Diego | San Diego | California | 92093 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Sarcoma Oncology Research Center | Santa Monica | California | 90403 | — |
| Innovative Clinical Research Institute | Whittier | California | 90602 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Holy Cross Michael & Dianne Bienes Comprehensive Cancer Center | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Affiliates | Ocala | Florida | 34471 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Maryland Oncology Hematology, | Rockville | Maryland | 20850 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Washington University Center for Advanced Medicine | St Louis | Missouri | 63110 | — |
| CHI Health St Francis, Saint Francis Cancer Treatment Center | Grand Island | Nebraska | 68803 | — |
| Oncology Hematology West PC, Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| University of New Mexico Cancer Research and Treatment Center | Albuquerque | New Mexico | 87102 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Columbia University | New York | New York | 10032 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Guthrie Clinical Research | Sayre | Pennsylvania | 18840 | — |
| St. Francis Cancer Center | Greenville | South Carolina | 29607 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Austin Midtown | Austin | Texas | 78705 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75251 | — |
| University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| The Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc., Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Northwest Cancer Specialists, P.C. | Vancouver | Washington | 98684 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02219711, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02219711 live on ClinicalTrials.gov.